
PMET Resources signs Matagami rail transshipment letter of intent
The proposed truck-to-rail handoff at Matagami still needs a commercial contract, with service pricing and upgrade contributions to be negotiated.

E.ON expects to match the EU grid grant with nearly HUF230B of its own spending across a four-year network program.

The proposed truck-to-rail handoff at Matagami still needs a commercial contract, with service pricing and upgrade contributions to be negotiated.

The 125-patient single-arm study had no control group, while Medtronic says U.S. payer coverage reaches 96% of commercial and Medicare insured lives.
The four-year plan covers existing lines in three states, but Entergy has given no installation start date or full project budget.
Two unnamed inference customers extend earlier deals, with QumulusAI targeting capacity turnover in December 2026 and early 2027.

The FDA label covers previously untreated adults with no known 17p deletion after a 282-patient trial against chemoimmunotherapy.

Among 109 treated patients, the median response lasted 12.1 months; the single-arm cohort offers no direct efficacy comparison.

Minnesota's attorney general says Xcel has not shown its Google agreement protects other customers from service and stranded costs.

The GL1 hole lies about 100 metres southeast of earlier drilling; assays from ten more holes in the completed program remain pending.
Congress delayed the new 0.4-milligram finished-product threshold to Dec. 11, leaving Tilray's disclosed U.S. drink formats above it.
State approvals cleared the Oct. 1 transfer of certain Ohio operations; AYR disclosed no cash proceeds or debt relief figure.
One petition is active and the other pending review; both would let Florida medical operators sell to adults if voters approve.
TransAlta sought US$19.9M for the first 90 days of a federal emergency order; FERC rejected the proposed allocation of those costs.
The TSX Venture company has issued US$10.5 million of secured convertible notes and will seek shareholder approval for preferred shares on Oct. 14.
We Energies says Oracle would take on part of its required nuclear power purchase; Oracle says the subscription needs Wisconsin commission approval.
AstraZeneca or Daiichi Sankyo will sponsor the planned breast cancer study, with all three companies sharing trial costs and retaining drug rights.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The Nevada lithium study assumes US$24,000 per tonne of lithium carbonate and US$2.77 billion in first-phase capital.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The company says the agency has set no new action date, while its U.S. launch target remains conditional on approval.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
Bitdeer's Oct. 3 update lists zero pure bitcoin holdings as of Oct. 2 but gives no sale price, proceeds or mining costs.
The Oct. 1 close follows a 25 million share proposal, but the completion notices give no final ownership percentage or cash proceeds to the parent.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
About 40 gas units are set for staged deployment from late 2026, with revenue expected to begin in the first quarter of 2027.

Marimaca's Oct. 1 update names no supplier, contracted volume or energization date for its preliminary five-year power framework.

Commerce's Bureau of Industry and Security authorised sales under specified terms; the company did not name an export buyer or shipment date.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The ARTG's Sept. 15 entry names Jupiter Research as manufacturer; Curaleaf also reports a Sept. 17 New Zealand WAND notification.

Colorado completed its review on Sept. 29; permit issuance requires verified warranties, and DOE mine-plan approval remains pending.

The uncontrolled Canadian trial enrolled 11 patients; seven were evaluable for pain, and validated data analysis remains underway.

Lifted Made closed the Kenosha building sale Sept. 29 and used US$841,110 to repay all its outstanding bank debt.